dabigatran has been researched along with ritonavir in 7 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (ritonavir) | Trials (ritonavir) | Recent Studies (post-2010) (ritonavir) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 5,419 | 1,291 | 2,772 |
| Protein | Taxonomy | dabigatran (IC50) | ritonavir (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 6.1 | |
| Bile salt export pump | Homo sapiens (human) | 2.085 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 2.65 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.1623 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.3 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2.458 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.067 | |
| Substance-K receptor | Homo sapiens (human) | 2.622 | |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | 2.35 | |
| Thromboxane-A synthase | Homo sapiens (human) | 0.076 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 4.4 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 2.1933 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 4.4 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2 | |
| Protease | Human immunodeficiency virus 1 | 4.9253 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Barco, S; Coppens, M; Middeldorp, S; Stroobants, AK; van de Kerkhof, D; van den Dool, EJ | 1 |
| Alfaro, RM; Brooks, KM; George, JM; Gordon, LA; Hadigan, C; Kellogg, A; Kumar, P; Lozier, J; McManus, M; Nghiem, K; Penzak, SR | 1 |
| Fulco, PP; Higginson, RT; Kakadiya, PP | 1 |
| Betti, M; Danzi, GB; Dellanoce, C; Giorgi-Pierfranceschi, M; Morandini, R; Palareti, G; Pan, A; Paoletti, O; Prandoni, P; Tala, M; Testa, S | 1 |
| Brown, JD; Cristofoletti, R; Farhan, N; George, JM; Gordon, LA; Hadigan, C; Kim, S; Kumar, P; Lingineni, K; Penzak, S; Schmidt, S | 1 |
| Lomakina, V; Sozio, SJ; Tekle, J | 1 |
1 trial(s) available for dabigatran and ritonavir
| Article | Year |
|---|---|
Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.
Topics: Adult; Antithrombins; Antiviral Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cobicistat; Dabigatran; Drug Interactions; Female; Healthy Volunteers; Humans; Intestinal Mucosa; Intestines; Male; Middle Aged; Ritonavir; Thrombin Time | 2017 |
6 other study(ies) available for dabigatran and ritonavir
| Article | Year |
|---|---|
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lopinavir; Male; Middle Aged; Protease Inhibitors; Pyridines; Ritonavir; Treatment Outcome; Vitamin K | 2014 |
Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.
Topics: Aged; Anti-HIV Agents; Cobicistat; Dabigatran; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Ritonavir | 2018 |
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antithrombins; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Dabigatran; Darunavir; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Italy; Lopinavir; Male; Pandemics; Patient Safety; Pneumonia, Viral; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thiazoles | 2020 |
Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Cobicistat; Dabigatran; Drug Interactions; Hemorrhage; Humans; Kidney Diseases; Risk Assessment; Ritonavir | 2021 |
Use of Apixaban in Atrial Fibrillation With Ritonavir-Boosted Antiretroviral Therapy: A Case Report.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; HIV Infections; Humans; Male; Pyridones; Ritonavir; Rivaroxaban; Stroke; Warfarin | 2023 |